Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -4.00% | -6.15% | +8.39% |
Financials (USD)
Sales 2024 * | 103M | Sales 2025 * | 76.06M | Capitalization | 131M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -50M | EV / Sales 2024 * | 1.27 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.72 x |
P/E ratio 2024 * |
-11.9
x | P/E ratio 2025 * |
-3.55
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | -4.00% | ||
1 week | -6.15% | ||
Current month | -1.18% | ||
1 month | -62.08% | ||
3 months | -38.69% | ||
6 months | +16.67% | ||
Current year | +8.39% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 1.68 | -4.00% | 1,618,989 |
24-06-03 | 1.75 | +2.94% | 1,247,477 |
24-05-31 | 1.7 | -2.86% | 953,744 |
24-05-30 | 1.75 | 0.00% | 1,651,680 |
24-05-29 | 1.75 | -2.23% | 2,788,394 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.39% | 136M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- CTMX Stock